Trial Profile
A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the efficacy, safety, and tolerability of MDCO-216 given as multiple weekly infusions in subjects with a recent acute coronary syndrome event
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs MDCO 216 (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms MILANO DRIVE
- Sponsors The Medicines Company
- 27 Nov 2016 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.
- 04 Nov 2016 New trial record